NVS
Novartis AG ADR
$161.93-1.85%
Setup
Watch
Buy Zone
$164.56-$172.79
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
39
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
NVS chart
Loading chart…
ADX
Weak or Absent12.3Long Term
Up ↑Intermediate Term
Up ↑Short Term
Range →Overall Quality39
RS Rating
71
relative strength
Fundamentals
52
Weak fund-Q
Volume Demand
68
+20% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Avoid
Entry
$164.56
Entry Zone
$164.56-$172.79
Stop / Risk
$151.4
RS Rating
71
Volume confirmed
No
Targets
$197.47 / $205.7
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $164.56–$172.79Stop $151.4Target $197.47 / $205.7
Market regimeRange
Quality39
RS Rating71
Above 50-MA+8.92%
Above 200-MA+6.42%
VolumeWeak
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
39
MarketRange
SetupWatch
ConfidenceExperimental · not backtested
Fund-Q52 · Weak
StatusAvoid
Stock Data
52-Week Range123 – 170
Price % Chg YTD17.45%
Price % Chg 4wk13.02%
50-Day Avg Vol2.0 Mil
P/E Ratio30.7
Market Cap$294B
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)-68.95%
Sales % Chg (Qtr)4.03%
EPS Growth 5y15.24%
Sales Growth 5y2.29%
Annual ROE24.62%
Gross Margin74.3%
Operating Margin30.47%
Net Margin18.14%
Debt / Equity1.30
Setup levels
Current price
$161.93
Pivot
$164.56
Distance to buy
-5%
52-week range
123.24-170.45
Trigger evidence
No active trigger evidence available.
Pattern levels: near highs
Financial health checks
3/5
Return on equity above 15%
ROE 24.62%
Net margin above 10%
Net margin 18.14%
EPS growing quarter on quarter
EPS q/q -68.95%
Sales growing quarter on quarter
Sales q/q 4.03%
Debt to equity below 1.0
D/E 1.30
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE24.62%
vs sector +2.0%
Net margin18.14%
vs sector +0.5%
Gross margin74.3%
vs sector +7.1%
EPS growth q/q-68.95%
vs sector -76.5%
Sales growth q/q4.03%
vs sector -14.7%
Debt / equity1.30
vs sector +0.65
Business quality
52
GradeWeak
EPS rating12
P/E30.7
Market cap$294B
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-10-28
Trigger date
—
Days on list
9
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.